Manchester Biorelate Secures Investment
Manchester-based Biorelate, a biomedicine technology platform, has secured Â£700,000 investment.
20:31 23 September 2018
Biorelate, a technology platform that uses artificial intelligence to efficiently curate data in biomedicine, has secured £700,000 in its latest funding round, which will enable it to expand its team as well as develop new products. The investment came from Maven Equity (£200,000), Cheshire Life Sciences (£150,000) and the Manchester Tech Trust Angels (£350,000).
Founded in 2014, the company’s goal is to curate data and information from clinical trials, patents, journals and other published literature so they can be easily accessed by pharmaceutical companies, researchers and medical students.
Founder Daniel Jamieson said: “We are building a technology platform to extract more value from data in science texts, 80% of which is unused.
“Our initial focus is in working with companies in the very early stages of drug discovery to help them make better use of this data on the path to producing viable new treatments.
“I’m absolutely thrilled to have Maven and the MTTA on board for this journey and to have the amazing Catapult Ventures team commit further.”
Gavin Bell, investment manager at Maven, said: “We’ve been impressed with Biorelate’s ability to generate growing demand from quality customers, in a short space of time.
“We can see the advantages of leveraging Biorelate’s technology, to derive bespoke data-driven insights from the vast array of published biomedical information.
“We are very much looking forward to working with Dan and the team through the next stage of their journey.”